Asgard Therapeutics

Don't miss out! Meet Asgard Therapeutics at #ISSCR2024 in Hamburg, Germany, from July 10-13, 2024! Join our co-founder and CEO Cristiana Pires as she speaks about in vivo direct reprogramming of tumor cells to dendritic cells as a new cancer immunotherapy modality. She will be speaking at the session: “Plenary VI: the clinical reality and promise of cell and gene therapies” on Saturday, July 13, 2024, from 10:45 AM – 11:05 AM CEST in Hall 1, Level 2. We’re excited to connect! #AsgardTherapeutics #ISSCR2024 #Immunooncology

Don't miss Asgard Therapeutics at #ISSCR2024 in Hamburg, Germany, from July 10-13, 2024!    Join our co-founder and CEO Cristiana Pires as she speaks about in vivo direct reprogramming of tumor cells to dendritic cells as a new cancer immunotherapy modality.    She will be speaking at the session: “Plenary VI: the clinical reality and promise of cell and gene therapies” on Saturday, July 13, 2024, from 10:45 AM – 11:05 AM CEST in Hall 1, Level 2.    We’re excited to connect with the global stem cell and regenerative medicine community!   #AsgardTherapeutics #ISSCR2024 #Immunooncology

🚀 Asgard Therapeutics is excited to share highlights from our successful 3rd Annual SAB meeting held in Lund. The SAB gathered to review key updates on our lead program, AT-108, designed to initiate efficient and personalized immune responses. Discussions centered on ongoing CMC and IND enabling studies, as well as strategic regulatory and clinical pathways, all crucial steps towards our goal of being IND-ready by mid 2026. Cristiana Pires, PhD, Co-Founder and CEO of Asgard Therapeutics, said: "We are thrilled to harness the translational expertise of our global SAB and benefit from the helpful feedback of Aurélien Marabelle, Ulrich Lauer, Joshua Brody, MD and Johanna Olweus, which have enabled us to refine our strategy and streamline our development process. Since our last meeting in September 2023, we achieved significant milestones, including closing a €30M Series A funding round. Their guidance will bring us closer to executing our Series A plans and advancing towards our first-in-human studies." #AsgardTherapeutics #AT108 #ImmunoOncology

Asgard Therapeutics announces the selection of Exothera for process development up to clinical Phases I/II manufacturing of lead program AT-108. AT-108 is a first-in-class, off-the-shelf gene therapy that leads to personalized and potent anti-cancer immune responses. This partnership marks a significant milestone for Asgard Therapeutics as we progress towards clinical development. We are thrilled to work with Exothera - a leading provider of nucleic acid and viral vector development and manufacturing services. Click the link in the comments below to read the full press release and discover more about our groundbreaking approach to in vivo direct cell reprogramming for cancer immunotherapy. #immunotherapy #biotech #manufacturing

Our next destination – Boston, USA! 🇺🇸     Asgard Therapeutics Co-founder and Head of Research, Fabio Rosa, will be at the event "Cancer Immunotherapy: From bench to bedside and back," taking place at the Joseph B. Martin Conference Center from June 10-12, 2024.     Meet Fabio during the Poster Presentation session on Tuesday, June 11th, from 12:15 - 1:45 p.m., Poster Assignment Number: 2-9.     Don't miss this opportunity to hear more about Asgard Therapeutics and our reprogramming technology. We look forward to seeing you there!     #AsgardTherapeutics #CancerImmunotherapy #BostonEvent 

Guess where Asgard Therapeutics is heading next? 🌍✨ We are returning to one of our favourite destinations - Portugal! 🇵🇹 Our Co-founder and Head of Research, Fabio Rosa, will be a Keynote Speaker at the VII iBiMED Symposium held at the University of Aveiro on May 23-24. Join us for Session 6 – Biomedical Therapeutics, where Fabio will talk about ‘Pioneering in vivo immune cell reprogramming for cancer immunotherapy.’ 📅 Date: May 24th   🕒 Time: 14:30 📌 Place: Auditorium Joaquim José da Cunha Don’t miss this opportunity to hear about Asgard Therapeutics and advancements in cancer immunotherapy. See you there! #AsgardTherapeutics #Immunotherapy #Networking

Ready for another exciting Lund community event? We’re heading to the Lund Immunotalks Symposium: 'Diverse path to unlocking immunity', and we couldn't be more excited! 🌟 This is the event for groundbreaking discussions on how cutting-edge approaches can be used for making progress in immunology research. 🧬💥 Join us on May 22nd, from 13:00 to 18:30, at Forum Medicum, BMC, Lund. Postdoctoral Scientist, Xavier Catena, is going to present at the poster session 'A cancer immunotherapy modality based on dendritic cell reprogramming in vivo'. ✨ Come by and meet the Asgard Therapeutics team throughout the day. See you there! 🚀 

🚀 Must-Attend Event! 🚀 Join us on June 18th at Medicon Village for the Lund Immunotalks seminar, where you can hear about clinical applications in immuno-oncology with insights from two globally distinguished experts. Meet Our Speakers: 👩⚕️ Johanna Olweus Head of the Department of Cancer Immunology at the Oslo University Hospital Comprehensive Cancer Center and Full Professor at the University of Oslo. Her research focuses on translational studies of T cell-based cancer immunotherapies, particularly the identification of novel immune receptors for use in gene and cell therapies. 👩⚕️ Inge Marie Svane Professor in Clinical Cancer Immune Therapy at the University of Copenhagen, Director of the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev and Gentofte Hospital, and Chief Physician specializing in melanoma at the Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. This is the great networking opportunity, connect with peers and experts during the Fika session, sponsored by Miltenyi Biotec, who will also have their team there! Save the Date: June 18th at Medicon Village's Inspira Building, from 9:00 to 11:00! We look forward to seeing you there! #LundImmunotalks #ImmunoOncology #Networking    

Another exciting event awaits those in Portugal! 🌟 Join us on May 13th at 11:00 as Fabio Rosa, co-founder and Head of Research of Asgard Therapeutics, takes the stage at Instituto Pedro Nunes Nonio Room, Building C, IPN. Fabio will talk about Asgard Therapeutics’ Journey in Healthcare Innovation: A reflection on key success factors, from scientific excellence to open innovation collaborations. Don't miss this incredible opportunity to connect, learn, and grow with Asgard Therapeutics! See you there! #AsgardTherapeutics #HealthInnovation #Networking

Meet Asgard Therapeutics at the Startup Capital Summit 2024 in Coimbra, Portugal, on May 10th! Our Co-founder and Head of Research, Fabio Rosa, will be sharing insights on the panel 'Internationalization: Distance Doesn't Matter'. 🗣️ 📅 Date: Friday, May 10th   ⏰ Time: 17:15-18:00   🏨 Room: Aeminium II We're excited to connect with you! #AsgardTherapeutics #StartupLife #Networking